XRCC2 and neoplasm: More recently, Chen et al. have demonstrated that delivery of the lentiviral vector containing promoter XRCC2 to target cancer-specific tumor cells with hyperactive HR genes holds great promise for in vivo tumor prognosis and therapy [63].